EIM
SCPH

Essex Investment Management’s scPharmaceuticals SCPH Stock Holding History

Essex Investment Management’s Portfolio SCPH Stock Details SCPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-40,373
Closed -$501K – 423
2018
Q1 		$501K Buy
+40,373
New +$543K 0.07% 269

Other funds holding SCPH

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Essex Investment Management's SCPH Position: Q2 2018 in Review

Essex Investment Management sold out of scPharmaceuticals (SCPH) in Q2 2018, closing a stake of 40,373 shares — an estimated $501K sold.

Essex Investment Management first reported a position in SCPH in Q1 2018 and held it in 1 quarter. The position peaked at $501K in Q1 2018. 41 funds tracked by Wall St. Rank hold SCPH as of Q2 2018.

  • Essex Investment Management reported no remaining scPharmaceuticals position as of Q2 2018 after selling out during the quarter.
  • Essex Investment Management sold 40,373 scPharmaceuticals shares in Q2 2018, an estimated $501K.
  • Essex Investment Management first reported a position in scPharmaceuticals in Q1 2018 and held it in 1 quarter.
  • Essex Investment Management's scPharmaceuticals position peaked at $501K in Q1 2018.
  • 41 funds tracked by Wall St. Rank held scPharmaceuticals as of Q2 2018.

Based on Essex Investment Management's 13F filing for Q2 2018, filed 17 Jul 2018.